A recent study found that breast cancer–specific survival in patients with invasive lobular carcinoma was inferior compared to patients with invasive ductal carcinoma. A recent study found that breast ...

Preoperative axillary ultrasound and MRI effectively predict sentinel lymph node status, guiding safe SLNB de-escalation in ...

Sichun Yang, PhD, a member of Case CCC's Molecular Oncology Program, and Alberto Montero, MD, a Developmental Therapeutics Program member, are looking for patient advocates for a follow-up study to ...

While researchers work to improve lobular breast cancer screening, innovative treatments are improving outcomes for patients with the condition, which is diagnosed in more than 40,000 Americans each ...

Dr. Schwartz answers the question: 'Difference between in situ breast cancers?' — -- Question: What is the difference between ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS)?

Rates of one type of breast cancer — invasive lobular carcinoma — have been rising in the United States more than three times faster than those of all other breast cancers combined over the past ...

Lobular breast cancer rates increased 2.8 percent per year over the past decade, compared with a 0.8 percent annual increase for all other breast cancers. Lobular breast cancer grows in a linear ...

When former public affairs consultant Leigh Pate was diagnosed with lobular breast cancer in 2013, she mistakenly thought it was called “globular.” She’d never heard of it before, even though lobular ...

A fast-rising form of breast cancer that's harder to detect on mammograms now makes up more than one in ten cases in the United States, according to a new report from the American Cancer Society (ACS) ...

Genomic alterations (GAs) associated with durability of benefit from trastuzumab deruxtecan (T-DXd), trastuzumab emtansine (T-DM1) and sacituzumab govitecan (SG) in metastatic breast cancer (MBC).